G. Michael Felker spends much of his time researching Heart failure, Internal medicine, Cardiology, Intensive care medicine and Heart disease. G. Michael Felker mostly deals with Ejection fraction in his studies of Heart failure. His study looks at the relationship between Internal medicine and fields such as Endocrinology, as well as how they intersect with chemical problems.
His studies in Cardiology integrate themes in fields like Clinical endpoint and Blood pressure. His research integrates issues of Management of heart failure, Epidemiology, Diuretic and Acute decompensated heart failure in his study of Intensive care medicine. His Heart disease study combines topics in areas such as Functional recovery, Disease progression, Myocarditis, Inotrope and Transplantation.
His scientific interests lie mostly in Heart failure, Internal medicine, Cardiology, Intensive care medicine and Ejection fraction. As a part of the same scientific study, G. Michael Felker usually deals with the Heart failure, concentrating on Placebo and frequently concerns with Clinical endpoint and Surgery. His study in the fields of Renal function, Proportional hazards model, Acute decompensated heart failure and Serelaxin under the domain of Internal medicine overlaps with other disciplines such as In patient.
His Cardiology study frequently involves adjacent topics like Blood pressure. The various areas that he examines in his Intensive care medicine study include Emergency department, Disease and Diuretic. His studies deal with areas such as Valsartan, Prospective cohort study and Ventricular remodeling as well as Ejection fraction.
His primary scientific interests are in Heart failure, Internal medicine, Cardiology, Ejection fraction and Natriuretic peptide. G. Michael Felker interconnects Biomarker, Clinical trial, Renal function and Intensive care medicine in the investigation of issues within Heart failure. The Renal function study which covers Blood pressure that intersects with Proportional hazards model.
In his research on the topic of Internal medicine, Inotrope is strongly related with Placebo. He studied Cardiology and Omecamtiv mecarbil that intersect with Contractility. His research in Ejection fraction intersects with topics in Valsartan, Prospective cohort study and Diastole.
Heart failure, Internal medicine, Cardiology, Ejection fraction and Clinical trial are his primary areas of study. His work carried out in the field of Heart failure brings together such families of science as Randomized controlled trial, Blood pressure and Intensive care medicine. In general Internal medicine, his work in Hazard ratio, Biomarker, Confidence interval and Nesiritide is often linked to In patient linking many areas of study.
His Cardiology study incorporates themes from Tolerability and Renal function. His study in Ejection fraction is interdisciplinary in nature, drawing from both Omecamtiv mecarbil, Cardiac function curve, Valsartan, Diastole and Inotrope. His Clinical trial research includes elements of Large cohort, Outcomes research, Risk stratification, Proportional hazards model and Pharmacotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.
G M Felker;R E Thompson;J M Hare;R H Hruban.
The New England Journal of Medicine (2000)
Diuretic Strategies in Patients with Acute Decompensated Heart Failure
G. Michael Felker;Kerry L. Lee;David A. Bull;Margaret M. Redfield.
The New England Journal of Medicine (2011)
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.
G. Michael Felker;Larry A. Allen;Stuart J. Pocock;Linda K. Shaw.
Journal of the American College of Cardiology (2007)
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial
Margaret M. Redfield;Horng H. Chen;Barry A. Borlaug;Marc J. Semigran.
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
John R Teerlink;Gad Cotter;Beth A Davison;G Michael Felker.
The Lancet (2013)
Ultrafiltration in decompensated heart failure with cardiorenal syndrome
Bradley A. Bart;Steven R. Goldsmith;Kerry L. Lee;Michael M. Givertz.
The New England Journal of Medicine (2012)
Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure.
Benjamin H Trichon;G.Michael Felker;Linda K Shaw;Christopher H Cabell.
American Journal of Cardiology (2003)
A standardized definition of ischemic cardiomyopathy for use in clinical research.
G.Michael Felker;Linda K Shaw;Christopher M O’Connor.
Journal of the American College of Cardiology (2002)
Decision Making in Advanced Heart Failure A Scientific Statement From the American Heart Association
Larry A. Allen;Lynne W. Stevenson;Kathleen L. Grady;Nathan E. Goldstein.
Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.
G.Michael Felker;Raymond L Benza;A.Bleakley Chandler;Jeffrey D Leimberger.
Journal of the American College of Cardiology (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: